Triptorelin

When ATH:
L02AE04

Characteristic.

Antitumor hormonal, synthetic analog of gonadotropin releasing hormone (GnRG). Available in the form of acetate.

Pharmacological action.
Antigonadotropnoe, antitumor, cytostatic.

Application.

Endometriosis (confirmed by laparoscopy when indicated to suppress ovarian function and no need for surgery), hysteromyoma (to reduce the size before surgical removal), symptomatic treatment of advanced hormone-dependent prostate cancer (alternative to surgical castration, suppression of testosterone secretion), early puberty, in vitro fertilization program, hypogonadotropic amenorrhea.

Contraindications.

Hypersensitivity (incl. to other GnRH analogues), men - hormone-independent prostate cancer, state after prostatectomy, metastases to the spine or urinary tract obstruction; women - osteoporosis (or an increased risk of clinical manifestations).

Restrictions apply.

Polycystic ovaries (when used in IVF).

Pregnancy and breast-feeding.

Contraindicated in pregnancy (adequate and well-controlled studies have been conducted) and during breastfeeding (unknown, whether triptorelin gets into breast milk).

Displaying, triptorelin that is toxic to the parent organism and exhibits embryotoxic properties when administered to rats at doses, exceeding the recommended human (based on body surface area) in 0,2; 0,8 and 8 time. Foetotoxic and teratogenic properties have been recorded.

In women of childbearing age before treatment should be deleted pregnancy. Women in the treatment it is necessary to use a non-hormonal methods of contraception.

Side effects.

From the nervous system and sensory organs: headache, sleep disturbance, mood lability, irritability, depression, asthenia, feeling tired, paraesthesia, blurred vision.

From the digestive tract: nausea, constipation or diarrhea, anorexia, weight gain, increase in liver transaminases, hypercholesterolemia.

With the genitourinary system: symptoms, associated with decreasing levels of sex hormones in the blood, incl. men - flushing, decreased libido, impotence, reducing the size of the testicles, gynecomastia; women - "smearing" discharge or dryness of the vaginal mucosa, decreased libido, pain during intercourse, flushing with profuse sweating.

On the part of the musculoskeletal system: myalgia, backache, deossification.

Allergic reactions: skin rash, hyperemia, itching at the injection site, anaphylactic shock, anaphylactoid reactions.

Other: a temporary increase in symptoms (incl. arthralgia, progression of hematuria or urinary disorders), Transient hypertension, anemia, swelling of the feet.

Overdose.

In case of overdose, immediately stop treatment and spend the appropriate triptorelin symptomatically.

Dosing and Administration.

P /, 1 once a day. The initial dose - 0,5 mg / day (during 7 days), maintenance dose - 0,1 mg / day (beginning with the 8th day).

In vitro fertilization, only one in / m injections per cycle of stimulation.

Depot: / m, n / a, by 3,75 mg every 28 days (women - from the third day of menstruation), within no more 6 Months.

Precautions.

The course is mandatory monitoring of plasma levels of sex hormones (men and women), PSA concentrations (Prostate-specific antigen) males, using ultrasound - the size of fibroids (rapid decrease in volume as compared with uterine fibroids size may cause bleeding and sepsis).

Menstruation usually occurs 3 month after the last injection, depot formulation, but in some cases, later.

The men at the beginning of treatment may increase testosterone levels in the blood, therefore, during the first weeks of treatment is recommended careful monitoring of the patients, especially metastases in the spine and in patients, suffering from disorders of urination, if necessary - symptomatic therapy.